
CARDIFF LEXINGTON CORPORATION
A PUBLIC HOLDING COMPANY

OTC: CDIX



Cardiff Lexington, through its subsidiary Nova Ortho and Spine, is profitably pioneering an innovative approach to healthcare management that offers elevated patient care to the uninsured patient population

INVESTMENT HIGHLIGHTS

5
Consecutive years of revenue growth

99.8%
Collection rate on settlements significantly outpaces industry average of 75-85%


11
Locations strategically dispersed throughout the Southeast U.S. and growing

180
Patients treated per month across all locations; capacity for substantial organic growth




- Orthopedics is one of the fastest-growing segments in US Healthcare
- Demand fueled by an aging population
- Recession resistant
- Innovative payor model
- Robust referral network
- Proven track record of growth and profitability

FY 2023 YOY RESULTS



CONSECUTIVE 5-YEAR REVENUE GROWTH



ENABLING CRITICAL ACCESS TO HIGH-QUALITY CARE FOR TRAUMATIC INJURY PATIENTS …

TRUSTED REFERRAL NETWORK

Patients are primarily referred through a growing network of trusted **physicians, physical therapists and chiropractors**

TRUE PARTNER THROUGH CLAIM LIFECYCLE

As emergency medical condition providers, Nova has **superior access to patient information** to determine the validity of each case and manage cases appropriately

LEADER IN SURGICAL TECHNIQUES & TECHNOLOGY


Nova Ortho and Spine's team of surgeons and specialists deliver **cutting-edge treatment options at state-of-the-art facilities**

QUALITY CARE AT ZERO COST TO THE PATIENT

Revenue is primarily provided by bodily injury policies, general liability policies, and personal injury protection policies, which **protects patients from high upfront costs**

…WHILE DRIVING SIGNIFICANT ECONOMIC RETURNS

- **Capital** provides Nova the ability to care for more uninsured patients and insulates the company from dependence on CMS (Medicare/Medicaid) or health insurance companies (HMOs or Blue Cross) for reimbursement
- **Payor mix** is almost exclusively comprised of automotive insurance companies, general liability carriers, and private pay
- **Longer A/R gestation period** (typically 18-24 months) is accounted for in pricing of patient care
- **99.8% collection rate** over past three years significantly outpacing industry average of 75-85%



INVESTOR RELATIONS CONTACT:

IMS Investor Relations
Cardiff@imsinvestorrelations.com
(203) 972-9200

SAFE HARBOR STATEMENT

This fact sheet may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management's beliefs, assumptions and expectations of the Company's future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in "Risk Factors" included in our filings with the Securities and Exchange Commission.